Diabetes Prevention Program in Schizophrenia [DPPS]

/Home/Diabetes Treatment/Clinical Trial Resources for Diabetes/Diabetes Clinical Trials - Recruiting

Diabetes Prevention Program in Schizophrenia [DPPS]

This study is currently recruiting participants.
Verified by McMaster University, July 2005
Sponsors and Collaborators: Hamilton Health Sciences
The Lawson Foundation
Ontario Mental Health Foundation

Information provided by: McMaster University
ClinicalTrials.gov Identifier: NCT00182494

Purpose
Diabetes is 2-5 times more common in schizophrenia and it is a preventable; but the current diabetes prevention guidelines are not suitable for implementation in the severely mentally ill population. The principles of diabetes prevention are essentially dietary regulation, increased physical activity and adjunctive use of oral anti-diabetic drugs (metformin). In a modified diabetes prevention protocol suitable for use in mentally ill population, we packaged the original guide lines with an adventure and recreation program based on principles of experiential learning, cognitive restructuring and behaviour modification. In this proposed study, we plan to evaluate the feasibility of adopting the new protocol, and examine its effectiveness in preventing diabetes.

Condition Intervention Phase
Diabetes Mellitus
Schizophrenia
Behavioral: Modified diabetes prevention protocol & Metformin
Phase IV

MedlinePlus related topics: Diabetes Schizophrenia
Drug Information available for: Metformin Metformin hydrochloride
U.S. FDA Resources
Study Type:Interventional
Study Design:Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:A Five Year, Prospective, Randomized, Blinded, Controlled Trial Comparing the Efficacy of a Modified Diabetes Prevention Protocol and the Standard Comprehensive Outpatient Care in Lowering the Incidence of New Onset Diabetes Among People Treated for Schizophrenia and Are at Risk to Develop Type II Diabetes Mellitus.

Further study details as provided by McMaster University:

Primary Outcome Measures:
1. Adherence/ability to run as designed /recruitment

2. Impact on modifiable diabetes risk factors

3. Impact on incidence of diabetes

Secondary Outcome Measures:
1. Adherence Rates for Diet, Exercise, Meds

2. Changes in lifestyle, Changes in eating patterns, Changes in activity patterns

3. Sustained changes in eating & activity patterns

Estimated Enrollment:200
Study Start Date:February 2005
Estimated Study Completion Date:January 2009

Detailed Description:
Rationale:

From large international RCT studies, Type 2 Diabetes can be prevented / delayed for overweight, pre-diabetic individuals by making basic lifestyle changes (regular moderate exercise, healthy eating habits) and using metformin or other insulin resistance inhibitor.
Individuals with schizophrenia are in particular need of preventative intervention and conventional approaches do not match their needs.
Research has not examined how to facilitate lifestyle changes in the lives of individuals with schizophrenia.
We need to…

Develop and evaluate innovative diabetes prevention strategies tailored to meet the needs of individuals with schizophrenia.
Research how to make it work for pre-diabetic individuals being treated for schizophrenia.
The effectiveness of the novel intervention will be tested using a prospective, randomized, controlled clinical trial. A multi-factorial design enables a 2 x 2 analysis of the independent effects of three interventions – a tailored lifestyle modification program, metformin, and the standard conventional intervention. There is no anticipated interaction effect between metformin and lifestyle interventions. Clients currently treated for schizophrenia at a community outpatient clinic will be screened for diabetes, and those who fulfill the inclusion criteria, and give written consent, following a three week run-in period, will be randomized to one of four groups to receive either: the experimental intervention with placebo, the experimental intervention with metformin or the conventional intervention with placebo or conventional intervention with metformin.

Eligibility
Ages Eligible for Study:18 Years to 65 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No
Criteria
Inclusion Criteria:

People who are at least 18 years old, diagnosed as having schizophrenia, confirmed through a structured clinical interview (SCID-P) for DSM IV, treated with antipsychotic drugs at least for 2 years and deemed clinically stable. Clinical stability is operationally defined as absence of a relapse warranting hospitalization in the preceding six months.
People who are deemed as “pre-diabetics” in accordance with the diagnostic criteria established by the American Diabetic Association (ADA, 2004) as following: impaired fasting glucose (IFG) indicating fasting plasma glucose ranging between 100-125 mg/dl or 5.6 - 6.9 mmol/l.; and impaired glucose tolerance (IGT) indicating 2-h post-load glucose ranging between 140-199 mg/dl or 7.8 - 11.0 mmol/l.
People who have gained > 10% body weight since??? Or body mass index > 24 kg/m², except Asian decent at 22 kg/m² or greater??
Competent to provide informed consent to voluntarily participate in the study.
Exclusion Criteria:

People who meet the criteria for diabetes, (i.e., repeat fasting blood glucose (FBG) >7 mmol/l or, 2 hr. post-load glucose >11.1 mmol. as determined by a 2 hr. glucose tolerance test (GTT)).
People with evidence of clinically significant liver disease, renal or gastrointestinal impairments, as suggested by clinical history and liver and kidney functions tests. Any impairment deemed clinically significant would be a relative contra-indication for the use of metformin.
Women in the child bearing age, who are not willing to use contraceptive measures.
People with other comorbid disorders such as clinically significant heart or lung disease that may prevent participation in various physical activities or disorders of glucose metabolism (e.g., Cushing’s Syndrome, Acromegaly, and chronic pancreatitis).
People with treatments that would interfere with participation or completion of the protocol (e.g., in shared care and planning to be discharged shortly from the clinic), or having a confounding effect on the measurement of the primary outcomes of the study (prescription weight loss drugs, lipid lowering agents?)
People with weight loss >10% in past 6 months
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00182494

Contacts
Contact: Lakshmi P Voruganti, MD 905-522-1155 ext 6355 vorugl@mcmaster.ca
Contact: Susan Strong, MSc 905-522-1155 strongs@mcmaster.ca

Locations
Canada, Ontario
McMaster University Recruiting
Hamilton, Ontario, Canada
Contact: Lakshmi P Voruganti, MD 905-522-1155 ext 6355 vorugl@mcmaster.ca
Contact: Susan Strong, MSc 905 522 1155 strongs@mcmaster.ca
Principal Investigator: Lakshmi P Voruganti, MD

Sponsors and Collaborators
Hamilton Health Sciences
The Lawson Foundation
Ontario Mental Health Foundation
Investigators
Principal Investigator: Lakshmi P Voruganti, MD McMaster University

Study ID Numbers:04-2417
First Received:September 14, 2005
Last Updated:September 14, 2005
ClinicalTrials.gov Identifier:NCT00182494 [history]
Health Authority:United States: Food and Drug Administration; Canada: Therapeutic Products Directorate, Health Canada

Keywords provided by McMaster University:
Schizophrenia, Diabetes, Weight gain, Antipsychotic drugs

Study placed in the following topic categories:
Metabolic Diseases
Metformin
Diabetes Mellitus
Endocrine System Diseases
Weight Gain
Body Weight
Schizophrenia
Mental Disorders
Diabetes Mellitus, Type 2
Psychotic Disorders
Endocrinopathy
Glucose Metabolism Disorders
Metabolic disorder
Schizophrenia and Disorders with Psychotic Features